Related Experiment Videos
ELITE II and Val-HeFT are different trials: together what do they tell us?
1University of Bergen, Cardiology Department, Central Hospital in Rogaland, Stavanger, 4011, Norway. trout@online.no
Insights
Two major trials, ELITE II and Val-HeFT, assessed angiotensin II receptor antagonists for heart failure. While complementary, differences in design necessitate careful interpretation for optimal patient treatment.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Symptomatic heart failure presents a significant morbidity and mortality challenge.
- Angiotensin II receptor antagonists (ARAs) are a class of drugs targeting the renin-angiotensin system.
- Previous studies suggested potential benefits of ARAs in heart failure management.
Purpose of the Study:
- To evaluate the efficacy and tolerability of selective angiotensin II receptor antagonists in patients with symptomatic heart failure.
- To compare the outcomes of the Losartan Heart Failure Survival Study (ELITE II) and the Valsartan Heart Failure Trial (Val-HeFT).
- To understand the role of ARAs in optimizing heart failure treatment.
Main Methods:
- The ELITE II trial investigated losartan in heart failure patients.
- The Val-HeFT trial investigated valsartan in heart failure patients.
- Both trials employed distinct primary hypotheses, study designs, and treatment regimens.
Main Results:
- Data from ELITE II and Val-HeFT provide complementary insights into ARA efficacy.
- Interpretation of trial data requires consideration of their methodological differences.
- The trials contribute to the understanding of optimal symptomatic heart failure management.
Conclusions:
- Angiotensin II receptor antagonists show potential in managing symptomatic heart failure.
- Further research is necessary to fully elucidate the role of ARAs in diverse heart failure populations.
- Optimal treatment strategies for heart failure continue to evolve with ongoing research.
Abstract:
The Losartan Heart Failure Survival Study (ELITE II) and the Valsartan Heart Failure Trial (Val-HeFT) both evaluated the efficacy and tolerability of a selective angiotensin II receptor antagonist on morbidity and mortality in patients with symptomatic heart failure. The trials differed, however, in terms of their primary hypothesis, study design, and treatment regimens, and this must be taken into consideration when comparing and interpreting the data from these studies. The data are in many ways complementary, and add to our understanding of the optimal treatment of symptomatic heart failure. Additional studies are needed, however, to fully define the role of angiotensin II receptor antagonists in the management of this very heterogeneous group of patients.